New Probiotic Targets 40 Million Sufferers of Antibiotic-Associated Diarrhea
Convenient 10-Day Course Has Consumer Appeal and May Improve Adherence to Antibiotic Therapy
(firmenpresse) - MIAMI, FL -- (Marketwire) -- 02/21/13 -- Miami-based bioceutical and nutritional supplement manufacturer Scimera BioScience® announced the launch of its novel probiotic formulation, Asprega ProPac, to address the gastrointestinal side effects of antibiotic therapy including antibiotic-associated diarrhea (AAD). Unique to ProPac, Scimera packages its probiotic in a convenient, affordable 10-day course to be taken along with a typical 10-day course of antibiotics.
Doctors and physician extenders in the U.S. prescribe more than 133 million courses of antibiotics each year, excluding hospital-based prescriptions. And among the patients who take these antibiotics, approximately 30%, or nearly 40 million, suffer from gastrointestinal distress and AAD. ProPac, which uses the same complex blend of 11 probiotic strains and saccharomyces boulardii yeast found in Scimera's Asprega product, addresses the "good bacteria" sometimes disturbed during antibiotic therapy.
"We have seen plenty of evidence over the past half-dozen years that probiotics can prevent antibiotic-associated diarrhea for about 50 to 60-percent of patients who suffer from symptoms," said Frederick Chaleff, M.D., president and CEO of Scimera BioScience and one of the key players in formulating Asprega. "Now, we can offer patients an affordable option to address the side effects from taking their antibiotics."
Asprega ProPac's novel packaging provides pharmacies and other retailers with significant opportunity for ancillary sales along with each antibiotic prescription filled. The launch of Asprega ProPac also holds potential to improve the likelihood that more patients taking antibiotics will complete their therapy.
At 20 billion CFUs, or "colony forming units," Asprega ProPac has more than double the potency of most probiotics. In addition, its special delayed-release capsule delivers maximum effectiveness deep in the digestive tract.
For more information about Scimera BioScience and its Asprega ProPac, visit .
Scimera Bioscience® develops cutting-edge Bioceuticals that address cardiovascular, immune system, bone and joint, gastrointestinal, respiratory, prostate, and a wide array of health issues. The Scimera Bioscience® Team is comprised of Physicians, Pharmacists, Chemists, Consumer Advocates and a Management Team with extensive clinical exposure and expertise, all with the goal of producing science-based health support.
Contact:
Alex Madeja
The Weinbach Group, Inc.
(305) 668-0070
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.02.2013 - 13:29 Uhr
Sprache: Deutsch
News-ID 1199551
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MIAMI, FL
Phone:
Kategorie:
Personal Care & Fitness
Anmerkungen:
Diese Pressemitteilung wurde bisher 147 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New Probiotic Targets 40 Million Sufferers of Antibiotic-Associated Diarrhea
"
steht unter der journalistisch-redaktionellen Verantwortung von
Scimera BioScience (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
